IP Verse

Methods Of Treating Bacterial Infections - EP3565551

The patent EP3565551 was granted to Melinta Therapeutics on Mar 20, 2024. The application was originally filed on Jan 8, 2018 under application number EP18735813A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3565551

MELINTA THERAPEUTICS
Application Number
EP18735813A
Filing Date
Jan 8, 2018
Status
Granted And Under Opposition
Feb 16, 2024
Publication Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKDec 20, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8680136
DESCRIPTIONWO8705297
OPPOSITIONUS2016339045
OPPOSITIONWO2013184845
SEARCHUS2016339045

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (TangoIII)", ClinicalTrials.gov - trial NCT03006679, (20161230), ClinicalTrials.gov - trial NCT03006679, URL: https://clinicaltrials.gov/ct2/show/NCT03006679?term=vaborbactam+AND+meropenem, (20181022), XP055517573
OPPOSITION- Anonymous, "Dose-finding, Pharmacokinetics, Safety, and Tolerability of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects With Serious Bacterial Infections (Tangokids)", ClinicalTrials.gov - Archive history for NCT02687906, (20161201), ClinicalTrials.gov - Archive history for NCT02687906, URL: https://clinicaltrials.gov/ct2/show/NCT02687906, (20181022), XP055517569
OPPOSITION- Anonymous, "Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults", ClinicalTrials.gov - Archive history for NCT02168946, (20161006), ClinicalTrials.gov - Archive history for NCT02168946, URL: https://clinicaltrials.gov/ct2/history/NCT02168946?A=18&B=18&C=merged, (20181022), XP055517572
OPPOSITION- Anonymous, "Efficacy, Safety, Tolerability of Carbavance Compared to Piperacillin/Tazobactam in Complicated Urinary Tract Infections (cUTIs), Including Acute Pyelonephritis (AP) in Adults", ClinicalTrials.gov Archive - Archive History for NCT02166476, (20161201), ClinicalTrials.gov Archive - Archive History for NCT02166476, URL: https://clinicaltrials.gov/ct2/history/NCT02166476?V_22=View#StudyPageTop, (20181022), XP055517550
OPPOSITION- W. J. Weiss et al, "B-078 Efficacy of Carbavance (Meropenem-RPX7009) against Carbapenem-resistant E.coli in a Murine UTI Infection Model", Abstracts Book, Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), American Society for Microbiology, US, US , (20150101), vol. 55, ISSN 0733-6373, pages 121 - 122, XP009515473
OPPOSITION- W J Weiss, Et Al., "Efficacy of Carbavance (Meropenem+RPX7009) against Carbapenem-resistant E. coli and K. pneumoniae in a Murine UTI Model", Abstract B- 078, Poster presentation - 55th ICAAC, 58th ICC, (20150917), XP055517551
OPPOSITION- Charlson, M.E. et al, "A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation", Journal of Chronic Diseases, (19870101), vol. 40, no. 5, doi:10.1016/0021-9681(87)90171-8, ISSN 0021-9681, pages 373 - 383, XP023088372
SEARCH- WEISS W J ET AL, "B-078 Efficacy of Carbavance (Meropenem-RPX7009) against Carbapenem-resistant E.coli in a Murine UTI Infection Model", ABSTRACTS BOOK, INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS & CHEMOTHERAPY (ICAAC), AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20150101), vol. 55, ISSN 0733-6373, pages 121 - 122, XP009515473 [X] 1-2,11 * the whole document * [Y] 1-2,8-15 [A] 3-7
SEARCH- W J WEISS ET AL, "Efficacy of Carbavance (Meropenem+RPX7009) against Carbapenem-resistant E. coli and K. pneumoniae in a Murine UTI Model", ABSTRACT B- 078, POSTER PRESENTATION - 55TH ICAAC, 58TH ICC, (20150917), XP055517551 [X] 1-2,11 * the whole document * [Y] 1-2,8-15 [A] 3-7

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents